- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | Ernexa regains Nasdaq compliance, continues trading on exchange | 2 | Investing.com | ||
| 09.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements | 207 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| 07.07. | Biotech-Unternehmen Ernexa Therapeutics beauftragt Haskell & White als neuen Wirtschaftsprüfer | 1 | Investing.com Deutsch | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.07. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development | 2 | GlobeNewswire (USA) | ||
| 24.06. | Ernexa Therapeutics completes second closing of securities offering | 1 | Investing.com | ||
| 24.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement | 1 | GlobeNewswire (USA) | ||
| 12.06. | Ernexa Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:15 an | 3 | Investing.com Deutsch | ||
| 11.06. | Ernexa Therapeutics registers 57M shares for resale | 2 | Seeking Alpha | ||
| 11.06. | Ernexa Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.06. | Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance | - | RTTNews | ||
| 10.06. | Ernexa Therapeutics announces 1-for-15 reverse stock split | 1 | Investing.com | ||
| 10.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split | 199 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| 09.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
| 14.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations | 133 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| 08.05. | D.Boral Capital: Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference | 245 | Newsfile | Cambridge, Massachusetts--(Newsfile Corp. - May 8, 2025) - Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May... ► Artikel lesen | |
| 07.05. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.04. | Ernexa reports promising cancer cell therapy study results | 2 | Investing.com |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,240 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
| BIOXXMED | 0,410 | +32,26 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,942 | +0,94 % | Ocugen expands advisory board and leadership team for gene therapy push | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 1,010 | -2,88 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,371 | -1,07 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,361 | 0,00 % | Vaxart, Inc.: Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq | - Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,650 | +1,85 % | Burcon NutraScience Corporation: Burcon to Showcase Chipotle Black Bean Protein Hummus at 2025 IFT FIRST Annual Event & Expo | Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,080 | -5,05 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | NSE - Affimed N.V. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| AIM IMMUNOTECH | 0,073 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements | NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA... ► Artikel lesen | |
| IMMUNIC | 0,935 | -2,40 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,075 | +0,27 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 8,200 | +18,16 % | CEL-SCI Corporation: CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer | Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market Patient access and reimbursement/sale in... ► Artikel lesen |
Das Unternehmen ERNEXA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -7,62 % bei einem Aktienkurs von 1,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.